<DOC>
	<DOC>NCT02949830</DOC>
	<brief_summary>The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of ALN-AS1 in AIP patients</brief_summary>
	<brief_title>A Study to Evaluate Long-term Safety and Clinical Activity of ALN-AS1 in Patient With Acute Intermittent Porphyria (AIP)</brief_title>
	<detailed_description />
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria, Erythropoietic</mesh_term>
	<mesh_term>Porphyria, Acute Intermittent</mesh_term>
	<criteria>Completed participation in Part C of study ALNAS1001 Not on a scheduled regimen of hemin Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception Willing and able to comply with the study requirements and to provide written informed consent Clinically significant abnormal laboratory results Received an investigational agent (other than ALNAS1) within 90 days before the first dose of study drug or are in followup of another clinical study History of multiple drug allergies or intolerance to subcutaneous injection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>Porphyria</keyword>
	<keyword>AIP</keyword>
	<keyword>Heme/Haem Arginate</keyword>
</DOC>